Powering Microbiome Research and Diagnostics
Our qPCR-based platform is transforming microbiome analysis by enabling high-volume precision microbiome profiling. Learn about our solutions.
Microbiome Profiling
Bio-Me is transforming microbiome analysis by making it possible to analyze hundreds of samples in less than a day, with high resolution and reproducibility and at an affordable cost. Combined with an exclusive biobank and extensive patient database, Bio-Me’s Precision Microbiome Profiling Platform (PMP™) enables the development of clinical tests that will improve health and well-being worldwide.
AS FEATURED IN
Microbiome Solutions
Bio-Me offers a range of proprietary solutions to support microbiome research and development.
Microbiome Analysis Services
We support academia and pharma researchers in microbiome analysis with accurate, rapid, and standardized solutions without the need of in-house bioinformatics capabilities. Learn more.
Diagnostics & Drug Development for Pharma
We support pharma and clinical researchers in drug and diagnostic test development with PMP™, enabling rapid and high throughput analyses down to species and strain level resolution, with excellent reproducibility. Learn more.
Preventive and Consumer Health
We offer high throughput, rapid and end-to-end solutions for companies working in preventive or consumer health. Learn more.
PARTNERS
We chose Bio-Me as our diagnostic partner based on the performance of the PMP™ technology and their experience in developing microbiome profiling tools with clinical relevance.
We found that the PMP™ quantitative PCR method was a useful tool to identify important microbial biomarkers in a large population cohort.
The PMP™ technology made it possible for us to quickly determine subclasses of IBD for the first time and identify optimal treatment regime for adolescents.
Latest news
Cell publication: Precision Microbiome Profiling (PMP™) demonstrates it diagnostic potential in groundbreaking work conducted at Gustave Roussy Cancer Institute
TOPOSCORE, a bacterial signature for reliably predicting response to immune checkpoint inhibitor treatment in cancer patients, has been successfully validated on PMP™, demonstrating the clinical utility of Bio-Me’s proprietary platform.
17 September, 2024Press Release: Bio-Me AS Announces Appointment of Arne Materna as Co-CEO alongside Dr. Warren Flood
Dr. Arne Materna has been appointed Co-CEO as of July 1st, 2024 to strengthen the company’s capitalization and continued commercial growth. Read More
12 September, 2024Bio-Me selected as a partner in the PREVALUNG EU program developing predictive biomarkers associated with lung cancer risk
The PREVALUNG EU program aims to implement cancer risk stratification tools and personalized interventions to intercept lung cancer in cardiovascular patients. Bio-Me’s Precision Microbiome Profiling (PMP™) was chosen for high-throughput gut microbiome profiling.
07 September, 2023Bio-Me’s technology used for identifying bacteria associated with appendicular lean mass in a Nature Communications publication
PMP™ was used in a recent study to identify gut microbial species that are directly associated with appendicular lean mass and bone mineral density. More than 5000 fecal samples from the HUNT Biobank in Norway were analyzed with PMP™.
27 April, 2023Bio-Me´s PMP™ platform demonstrates its diagnostic and prognostic applicability in pediatric IBD
PMP™ was used in a recent study to explore the gut microbiome of children with inflammatory bowel disease (IBD), symptomatic non-IBD, and healthy children. Diagnostic, Phenotype and Prognostic Indexes were constructed based on PMP™ data with very good discriminating properties.
05 August, 2022Bio-Me strengthens its international commercial team with key hire
Bio-Me has employed Dr. Anne-Grethe Reichelt as part of the company’s plan to widen commercial adoption of their existing product portfolio and launch new products under development. Read More
04 July, 2022
